### Abstract

Patients are eligible for accrual onto a phase I autologous tumour vaccine clinical trial if their resected and dissociated tumour achieves a minimum viable cell count. Because tumour pre-processing and cell count determination are expensive, there has been developed a screening procedure based on tumour mass to screen out those tumours unlikely to yield sufficient viable cells. If θ is the ratio of the expected benefit of an accrual onto the study to the cost of tumour pre-processing and cell counting, then we maximize long-run benefit by pre-processing and counting only those tumours whose masses exceed a cutoff m(c), such that Pr(sufficient tumour cells/mass = m(c)) = 1/θ. We derive algorithms for estimating m(c) and evaluate them under a variety of assumptions concerning the cell count/mass relationship. These include explicit equations for m(c) under parametric assumptions as well as more general algorithms based on non-parametric smoothing techniques. We show that when θ deviates substantially from 2, these methods outperform simple inverse interpolation.

Original language | English (US) |
---|---|

Pages (from-to) | 2099-2110 |

Number of pages | 12 |

Journal | Statistics in Medicine |

Volume | 14 |

Issue number | 19 |

State | Published - 1995 |

Externally published | Yes |

### Fingerprint

### ASJC Scopus subject areas

- Epidemiology

### Cite this

*Statistics in Medicine*,

*14*(19), 2099-2110.

**An application of decision theory to patient screening for an autologous tumour vaccine trial.** / Shannon, W. D.; Bryant, J.; Logan, Theodore; Day, R.

Research output: Contribution to journal › Article

*Statistics in Medicine*, vol. 14, no. 19, pp. 2099-2110.

}

TY - JOUR

T1 - An application of decision theory to patient screening for an autologous tumour vaccine trial

AU - Shannon, W. D.

AU - Bryant, J.

AU - Logan, Theodore

AU - Day, R.

PY - 1995

Y1 - 1995

N2 - Patients are eligible for accrual onto a phase I autologous tumour vaccine clinical trial if their resected and dissociated tumour achieves a minimum viable cell count. Because tumour pre-processing and cell count determination are expensive, there has been developed a screening procedure based on tumour mass to screen out those tumours unlikely to yield sufficient viable cells. If θ is the ratio of the expected benefit of an accrual onto the study to the cost of tumour pre-processing and cell counting, then we maximize long-run benefit by pre-processing and counting only those tumours whose masses exceed a cutoff m(c), such that Pr(sufficient tumour cells/mass = m(c)) = 1/θ. We derive algorithms for estimating m(c) and evaluate them under a variety of assumptions concerning the cell count/mass relationship. These include explicit equations for m(c) under parametric assumptions as well as more general algorithms based on non-parametric smoothing techniques. We show that when θ deviates substantially from 2, these methods outperform simple inverse interpolation.

AB - Patients are eligible for accrual onto a phase I autologous tumour vaccine clinical trial if their resected and dissociated tumour achieves a minimum viable cell count. Because tumour pre-processing and cell count determination are expensive, there has been developed a screening procedure based on tumour mass to screen out those tumours unlikely to yield sufficient viable cells. If θ is the ratio of the expected benefit of an accrual onto the study to the cost of tumour pre-processing and cell counting, then we maximize long-run benefit by pre-processing and counting only those tumours whose masses exceed a cutoff m(c), such that Pr(sufficient tumour cells/mass = m(c)) = 1/θ. We derive algorithms for estimating m(c) and evaluate them under a variety of assumptions concerning the cell count/mass relationship. These include explicit equations for m(c) under parametric assumptions as well as more general algorithms based on non-parametric smoothing techniques. We show that when θ deviates substantially from 2, these methods outperform simple inverse interpolation.

UR - http://www.scopus.com/inward/record.url?scp=0029079672&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029079672&partnerID=8YFLogxK

M3 - Article

VL - 14

SP - 2099

EP - 2110

JO - Statistics in Medicine

JF - Statistics in Medicine

SN - 0277-6715

IS - 19

ER -